Amicus Therapeutics Inc.
Amicus Therapeutics Reports Full-Year 2024 Results and Provides 2025 Guidance
Summary
Amicus Therapeutics announced its financial results for the fiscal year ended December 31, 2024, reporting a 33% year-over-year increase in total revenue to $528.3 million. The company achieved a GAAP net income of $14.7 million for Q4 2024 and anticipates positive GAAP net income during H2 2025. For 2025, Amicus provided financial guidance with total revenue growth expected between 17-24%, and non-GAAP operating expenses estimated at $350-370 million. The company also highlighted progress in commercializing its treatments for rare diseases, including new pricing and reimbursement agreements.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement